3 publishers · first seen Wed, 04 Nov 2026 04:37 UTC · updated Fri, 06 Nov 2026 13:17 UTC
The Therapeutic Goods Administration (TGA) has approved Novo Nordisk's Wegovy (semaglutide) pill for use in Australia, marking the first time a GLP-1 weight-loss tablet has been cleared for use in the country. Previously, Australians could only access GLP-1s through weekly injections. The pill, which comes in four strengths (1.5mg, 4mg, 9mg, and 25mg), is intended for weight management and reducing the risk of major adverse cardiovascular events in eligible adults. The TGA is yet to review the packaging and production processes to ensure they meet quality standards before the product is released. The approval follows similar endorsements in the UK and the US, where demand for the drug surged upon its market entry.
Content auto-generated. May contain inaccuracies.